Contemporary therapy of colorectal tumors;A colorectalis daganatok korszerü kezelése

Lege Artis Medicinae

Volumn 15, Issue 3, 2005, Pages 177-186

  László, Lakatos ^a   László, Lakatos Péter ^b  

^a I Sz Belgyógyászati Osztály ^*  (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Adjuvant chemo radiotherapy; Biomodulating agents; Colorectal tumours

Indexed keywords

EID: 70449494544     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Parkin DM. Global cancer statistics In the year 2000. Lancet Oncol 2001; 2(9): 533-43.
2. Ottó S, Kásler M. Rákmortalitás és Incidencia hazánkban, az európai adatok tükrében. Magyar Onkológia 2002; 46: 111-117
3. Gill S, Thomas RR, Goldberg RM. Review article: colorectal cancer chemotherapy. Aliment Pharmacol Ther 2003; 18: 683-692
4. McArdle C, Hole D. Impact of variability among surgeons on post operative morbidity and mortality and ultimate survival. Br Med J 1991; 302: 1501-1505
5. Armban G, Nilsson E, Halbook O, et al. Local recurrence following total mesorectal excision for rectal cancer. Br J Surg 1996; 83: 375-379
6. Nocum S, Midgley R, Kerr DJ. Colorectal cancer. Acta Oncol 2003; 42: 263-275
7. Láng I. A colorectalis carcinoma multldlsciplinaris szemléletü belgyógyászati-onkológiai kezelése. LAM 2001 ;11(2): 118-129
8. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resecten colon carcinoma. N Engl J Med 2000; 322: 352-358
9. Piedbois P, Michiels S, for the Meta-Analysis Group in Cancer. Survival benefit of 5-FU/leucovorln over 5-FU bolus In patients with advancer colorectal cancer: an updated meta-analysis based on 2751 patients. Proc Am Soc Clin Oncol 2003; 22: A 1180.
10. QUASAR Collaborative Group. Comparison of fluorouracil with additive levamisole, higher-dose follnic acidor both as adjuvant chemotherapy for colorectal cancer: a randomized trial. Lancet 2000; 355: 1588-96.
11. Haydon A. Adjuvant chemotherapy In colon cancer: what Is the evidence? Intern Med J 2003; 33: 119-24.
12. Meta-analysis Group in Cancer. Efficacy of Intravenous continuous Infusion fluorouracil compared with bolus administration In advanced colorectal cancer. J Clin Oncol 1998; 16(1): 301-308
13. de Gramont A, Bosset J, Milan C, et al. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorinand fluorouraclil bolus plus continuous Infusion for advanced colorectal cancer: French intergroup study. J Clin Oncol 1997; 15(2)808-815
14. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capeclitabine versus Intravenous fuorouracl plus leucovorin as first-line treatment In 605 patients with metastatic colorectal cancer: reults of a randomizen phase III. study. J Clin Oncol 2001 ; 19(8) :2282-2292
15. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with Intravenous fluorouracil plus leucovrin In patients with metastatic colorectal cancer: results of a large phase III. study. J Clin Oncol 2001, 19(21)4097-4106
16. Braun AH, Achterrath W, Wilke H, et al. New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 2004; 100:1558-1577
17. Cats A. New developements In systemic chemotherapy In advanced colorectal cancer. Scand J Gastroenterol 2003; 38(Suppl 239):78-86.
18. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan In the treatment of advanced colorectal cancer In chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15(1): 251-260
19. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;353:1413-1418
20. Douillard JY, Cunningham D, Roth AD, et al. I rinotecan combined with fluorouracil compared with fluorouracil alone as firts-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047
21. Saltz LB, Cox JV, Blanke C, et al. I rinotecan plus fluorouracil and leucovorln for metastatic colorectal cancer. I rinotecan Study Group. N Engl J Med 2000; 343: 905-914
22. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment In advanced colorectal cancer. J Clin Oncol 2000; 18(19):2938-2947
23. Giacchetti S, PerpointB, Zidani R, et al. Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment ot metastatic colorectal cancer. J Clin Oncol 2000; 18(1): 136-147
24. Goldberg RM, Sargent D, Morton FR, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations In patients with peviously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
25. Gamelin L, Boisdron-Celle, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium Infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer Clin Cancer Res 2004; 10: 4055-4061
26. Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI In metastatic colorectal cancer (MCRC): final result of a Phase III study. Proc Am Soc Clin Oncol 2001; 20:494a
27. Schlag PM, Benhidjeb T Resection and local therapy for liver metastases. Best Pract Res Clin Gastroenterol 2002; 16: 299-317.
28. Van Cutsem E, Verslype C, Demedts I. The treatment of advanced colorectal cancer: where are we now and where do we go? Best Practice Res 2002;16:319-330
29. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid In colonic B2 colon cancer. J Clin Oncol 1999; 17: 1356-1363
30. Mamounas E, Wieland S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy In patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical, Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349-1355
31. NIH Consensus Conferenc. Adjuvant therapy for patienst with colon and rectal cancer. JAMA 1990; 264: 1444-1450
32. Wu JS, Fazio VW. Management of rectal cancer. J Gastrointest Surg 2004; 8: 139-149
33. Jansson-Frykholm G, Olimelius G, Pahlam L Pre-operative or postoperative Irradiation In adenocarcinoma of the rectum: final treatment results of a randomised trial and an evaluation of late secondary effects. Dis Colon Rectum 1993;36:564-572
34. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: asystematic overview of 8507 patients from 22 randomised trials. Lancet 2001;358:1291-304.
35. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monothetapy and cetuximab plus irinotecan In irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
36. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292-302.
37. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bavacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
38. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Eng J Med 2001;345:1091-7.
39. Kralovánszky J, Besznyák I, Köves I, et al. A timidilát szintézis enzimeinek prognosztikai szerepe emberi colorectalis daganatokban. Magyar Onkol 1997;41:94-9.
40. Ribic CM, Sargent DJ, Moore MJ, et al. Tuor microsatellite Instability (MSI) status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-257
41. Kahlenberg MS, Sullivan JM, Witmer DD, Petrelli NJ. Molecular prognostics In colorectal cancer. Surgical Onkol 2003; 173-186
42. Gill S, Goldberg RM. First-line treatment strategies to Improve survival In patients with advanced colorectal cancer. Drugs 2004;64(1):27-44.